Concordia Healthcare Corp. T.CXR.R

RE:Huge Volume Again Today

[lnvestor198]

DON'T BUY	Brian Madden	This is about as toxic as they come. Integrity of financial reporting is in question. He is not a fan of pretend earnings. The stock chart is badly broken. The business model is under heavy attack in the US. The bonds are CCC rated. / Be the first to comment	Price: $4.490 Subject: CANADIAN Bias: BULL Owned: Unknown
2016-10-28	DON'T BUY	Bruce Campbell (1)	It is uninvestable. It would be a speculative buy. They are generating cash now but there is so much debt and they don’t have a CEO. A year from now it will either very low or very high. The leverage works both ways. He recommends trading it. / Be the first to comment	Price: $4.490 Subject: CANADIAN LARGE Bias: SELECTIVE Owned: No
2016-10-26	DON'T BUY	Cole Kachur	The pharmaceutical space has not fared well in the US or Canada. This is a high debt company where the future is really uncertain. He doesn’t see any reversal to this major downtrend. / Be the first to comment	Price: $5.200 Subject: CANADIAN Bias: UNKNOWN Owned: No
2016-10-20	DON'T BUY	James Hodgins	It is a call option on whether the debt holders will start declaring bankruptcy. The strategy had a lot of merit. They made a mistake by taking more debt for their UK acquisition when the financing was not fully lined up for it. Brexit caused the company to decline, but the debt was in US$. It is crushing the company. / Be the first to comment	Price: $5.250 Subject: MARKET NEUTRAL INVESTING: SMALL/MID-CAP Bias: NEUTRAL Owned: Unknown
2016-10-19	DON'T BUY	Gavin Graham	Looking at what the price used to be, doesn’t mean this is cheap, it just means that the price was really, really high. Whenever a company’s market cap gets bigger than the Royal Bank, you know you are in trouble. Avoid. / Be the first to comment	Price: $4.720 Subject: NORTH AMERICAN/GLOBAL - LARGE Bias: UNKNOWN Owned: Unknown
2016-10-05	SELL	Brendan Caldwell	It has a lot of issues. It has the whole US system that is focused on the drug sector. The basic model was to take over drugs and patents, and to repurpose them or at least reprice them to higher levels. There is an immense amount of debt. When regulators smell blood, they circle and attack, and do not stop. Any sort of accounting irregularity never gets better. / Be the first to comment	Price: $6.100 Subject: CANADIAN VALUE Bias: UNKNOWN Owned: No
2016-10-04	COMMENT	Jerome Hass	Doesn’t think there is any probability of a recovery. It has a lot of issues ahead of it. In the UK, the NHS tabled a bill that will essentially directly affect the company in bringing down drug prices. In the last conference call, they reduced their guidance significantly. Also, they are now starting to get generic competition in the US, which was not foreseen. They have a lot of debt, and it is not inconceivable they could go to zero. / Be the first to comment	Price: $5.970 Subject: CANADIAN MID-CAPS & LONG/SHORT STRATEGIES Bias: UNKNOWN Owned: Unknown
2016-09-30	SELL	Ryan Modesto	Had liked this in the past. Their most recent quarter was brutal. It seemed like management was blindsided by the results. He got out at around $13. Over the next 3 months, no fund manager is going to want to hold this in their portfolio. / Be the first to comment	Price: $7.120 Subject: CANADIAN SMALL & MIDCAPS Bias: UNKNOWN Owned: No
2016-09-29	SELL	Peter Imhof	He prefers to cut losses because of the amount of debt on the books. When you get into trouble you still have to fund all that debt. He doesn’t see the company coming back. Cut your losses. / Be the first to comment	Price: $7.120 Subject: NORTH AMERICAN - SMALL Bias: BULLISH on SMALL CAPS Owned: Unknown
2016-09-21	PARTIAL SELL	Bruce Campbell (2)	A real tough one, and he is watching with interest. Looking at the balance sheet, you have to be really concerned in that they probably have negative equity. Also, their drugs have not been performing very well. There are headwinds in their recent acquisition from the UK. In the last little while, he has noticed that some value managers are starting to pick up the stock. He would like to see a trend change in revenue and EBITDA. / Be the first to comment	Price: $7.120 Subject: CANADIAN Bias: CAUTIOUS Owned: No
2016-09-20	SELL	Andy Nasr	At the time, this was a compelling pitch. You were buying drugs that were mispriced and were making a lot of money. It is really difficult when looking at a highly leveraged company like this to justify a turnaround. They are going to have to reduce debt and sell off some assets. In the meantime, the regulatory environment is not very favourable at all. / Be the first to comment	Price: $7.120 Subject: REITS, GLOBAL & MACRO STRATEGY Bias: UNKNOWN Owned: No
2016-09-19	SELL	Teal Linde	The gig is up in that whole business model. They started hiking up prices and getting aggressive on sales tactics. They are facing upcoming generic competition. / Be the first to comment	Price: $7.120 Subject: NORTH AMERICAN Bias: BULLISH Owned: Unknown
2016-09-16	SELL	William Chin	2014 to mid-2016 is a big mountain of oversupply on the chart. No buyers have emerged. There is continued selling pressure. He wouldn’t touch this. Today is a very good day to see if there is capitulation. You need a very strong close, much higher than the intraday low. If you can close off the low with good volume, and if there is good price action on Monday, then you might have seen capitulation. Capitulation is only one of the preconditions of a rally. / Be the first to comment	Price: $7.120 Subject: TECHNICAL ANALYSIS & MACRO STRATEGY Bias: UNKNOWN Owned: Unknown
2016-09-15	DON'T BUY	Daniel Lloyd	The debt is just so overwhelming. He is not sure they are going to be able to fix the problems with the balance sheet. / Be the first to comment	Price: $8.750 Subject: CANADIAN Bias: BEARISH on BONDS Owned: No
2016-09-13	SELL	Christine Poole	(Market Call Minute.) Doesn’t think there is any visibility going forward. / Be the first to comment	Price: $8.520 Subject: NORTH AMERICAN - LARGE Bias: UNKNOWN Owned: Unknown

Showing 1 to 15 of 182 entries

<<<12345>>>

Post Comment

5 Comments

uptick

October 14th 2015 at 10:14am

I hope this company drops to zero for ethical reasons.

barney11